



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	321553	VitaQIK Liposomal Spray D3 & K2
ARTG entry for	Medicine Listed	
Sponsor	Phytologic Holdings Pty Limited	
Postal Address	PO Box 6193, Alexandria, NSW, 2015 Australia	
ARTG Start Date	9/08/2019	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . VitaQIK Liposomal Spray D3 & K2

Product Type	Effective Date
Single Medicine Product	2/03/2021

Permitted Indications

- Maintain/support general health and wellbeing
- Maintain/support bone health
- Maintain/support bone strength
- Help maintain/support bone mineralisation
- Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life
- Maintain/support joint health
- Maintain/support healthy cardiovascular system function
- Maintain/support immune system health
- Maintain/support healthy immune system function
- Maintain/support muscle function
- Maintain/support healthy neuromuscular system/function
- Maintain/support absorption of dietary (state vitamin/mineral/nutrient)
- Maintain/support (state vitamin/mineral/nutrient) levels in the body when sun exposure is inadequate
- Maintain/support (state vitamin/mineral/nutrient) levels in the body
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency in elderly individuals

Indication Requirements

- Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).
- Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.
- Product presentation must not imply or refer to serious cardiovascular conditions.
- Product presentation must not imply or refer to serious musculoskeletal or neurological conditions.
- Product presentation must not imply or refer to serious immunological diseases.
- If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).



Australian Government
Department of Health
 Therapeutic Goods Administration

Indication only for use for medicines that contain vitamin D as an active ingredient. The medicines may only contain a maximum recommended daily dose of 25 micrograms or less of vitamin D and as a minimum, also contain at least 25% of the RDI in the recommended daily dose of vitamin D.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Contains sorbates' (or word to this effect) if medicine contains two or more sorbate sources OR 'Contains [insert the approved name of sorbate source used]' (or words to this effect) if medicine contains one sorbate source.

Contains benzoates' (or words to this effect) if the medicine contains two or more benzoate sources or 'Contains [insert the approved name of benzoate used]' (or words to this effect) if product contains one benzoate source.

Contains ethanol or contains alcohol.

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 . Formulation 1

Dosage Form Oral Liquid

Route of Administration Oral

Visual Identification

Active Ingredients

colecalfiferol	.0125 mg/mL
menaquinone 7	5 microgram/mL

Other Ingredients (Excipients)

- Acacia
- citric acid
- d-alpha-tocopherol
- ethanol
- Flavour
- fractionated coconut oil
- glycerol
- lecithin
- Lemon Oil
- liquid glucose
- menthol
- potassium sorbate
- purified water
- silicon dioxide
- sodium ascorbate
- sodium benzoate
- thaumatin

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.